ClinicalTrials.gg
Active, not recruitingNCT06981611Updated Aug 12, 2026

Vulvodynia Intervention: the Effect of Multimodal Treatment for Provoked Vulvodynia

An interventional study of Vulvodynia Intervention: a multimodal treatment for provoked vulvodynia in Vulvodynia (Chronic Vulvar Pain), sponsored by Karlstad University. Active, not recruiting at 1 site in Sweden. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Karlstad University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of this project is to develop and evaluate a multimodal treatment for provoked vulvodynia, by addressing the following specific research questions:

  1. What is the feasibility and acceptability of this multimodal treatment protocol?
  2. What are the effects on pain and psychosexual health?
  3. How is the treatment perceived by patients, clinicians and stakeholders in the health care setting, and how do they view the possibilities for implementation?

Participants will be recruited through their health care unit and receive a multimodal treatment. The treatment consists of individual sessions with different professionals, in total 11 sessions over a time period of four months. It is possible to involve partners in the treatment during two of the treatment sessions. The majority of the sessions are digital video meetings but some are conducted at the health care unit. The treatment are based on physiological and psychosocial components that have previously shown positive effects for individuals with vulvodynia, and includes both educational and practical elements.

The participants will:

  • Undergo a gynecological examination and a psychological assessment to determine if the treatment is suitable for their condition
  • Undergo a multimodal treatment
  • Complete questionnaires regarding their pain, physical tension, psychosexual and relational health and questions about the treatment
  • Be asked to participate in an interview about their experience of the treatment and intimacy
Read the detailed description

The study design consists of a mixed-methods design, where different methods are applied in the various sub-studies of the project.

Study 1, is an effectiveness evaluation, applying a sequential single case experimental AB design (SCED) with randomized baseline length, replicated across five healthcare contexts (n≈10-15 per unit, total N≈50-75).

Potential participants will be informed about the study at their health care unit and answer a few questions digitally to ensure that participation in the study is appropriate for them. An assessment will then be conducted and questions will be asked about the pain, psychological, sexual and relational health, and a diagnostic interview will be conducted to exclude other psychological issues that needs to be prioritized before vulvodynia treatment. After the assessment interview and inclusion, participants will be randomized to a 4, 5, or 6 week baseline period. Thereafter, the treatment will begin. During the baseline and treatment period, participants will complete a short self-assessment questionnaire, twice a week, to measure pain (primary outcome) and other key variables. To facilitate the repeated assessments, we will use the m-Path app, which was developed by KU Leuven University in Belgium to easily evaluate treatment for both patients and therapists. In addition to the repeated assessments, the treatment will be evaluated through a comprehensive web-based self-assessment questionnaire before and after the intervention and at a six-month follow-up, using the secure survey system called Survey and Report. through Karlstad university. The outcome measures are based on the ongoing work by the Swedish Agency for Health Technology Assessment and Assessment of Social Services.

Study 2, is a qualitative evaluation and initial assessment of the possibilities for implementing the treatment in the Swedish healthcare context.

Individual interviews with patients will be conducted and questions will be asked regarding their experience of the treatment model. Focus group interviews will be conducted with practitioners and questions will be asked regarding relevance, relative advantages, consistency with standard practices, usability, and adaptability. Since the treatment will be carried out in five healthcare units with different organizational and practical conditions, questions will specifically address unit-specific aspects that therapists and patients perceive as having facilitated or hindered the implementation and what could be improved in both treatment content and execution. The questions are based on the recommendations of the Swedish National Board of Health and Welfare and the Public Health Agency regarding the initial assessment of implementation possibilities.

To obtain the healthcare organization's perspective on implementation possibilities, interviews will be held with health care stakeholders within the participating healthcare units. These interviews will also focus on relevance, relative advantages, consistency with standard practices, usability, and adaptability.

The individual and focus group interviews will be conducted in person at the health care units or through digital video meetings. Data from focus group interviews and individual interviews will be recorded by audio, transcribed, and analyzed according to standard qualitative analysis methods, primarily inductive empirically driven Thematic Analysis (TA).

02

Conditions studied

  • Vulvodynia (Chronic Vulvar Pain)

Keywords

  • Vulvodynia
  • Provoked vulvodynia
  • multimodal treatment
  • cognitive behavioral therapy
  • cbt
  • couple treatment
  • single-case experimental design
  • sced
  • chronic pain
  • Vulvodynia Intervention
03

In context

Vulvodynia

117 studies on the registry are indexed under Vulvodynia; 21 are open to participants now.

This study's planned enrollment of 50 is close to the median of 46 across 89 interventional studies indexed under Vulvodynia.

Browse Vulvodynia studies →

Lead sponsor

Karlstad University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Biological sex: Female 18-40 years old Provoked vulvodynia

Exclusion criteria

Exclusion Criteria:

  • Severe psychological issues that should be prioritized before vulvodynia treatment (e.g., substance abuse, psychosis)
  • Ongoing pregnancy
  • Childbirth within the last year
  • Post-traumatic stress disorder (PTSD) related to sexual trauma
  • Insufficient mastery of the Swedish language
  • No experience of vaginal sex, as vaginismus might be suspected, which requires different treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Vulvodynia Intervention: a multimodal treatment for provoked vulvodynia

    A multimodal treatment consisting of approximately 11 treatment sessions, for provoked vulvodynia. Working with goal-directed behavior change that has both physiological and psychosocial components. The treatment sessions will be conducted with various professionals, via digital video meetings and meetings at the health care facilities. The first five sessions are conducted weekly, and the last six sessions are conducted biweekly. A follow-up session is conducted three months after the end of the treatment. Repeated measurements (twice a week) are being collected throughout this period.

    Behavioral: Vulvodynia Intervention: a multimodal treatment for provoked vulvodynia

  • No intervention
    Randomized to waiting period of 4, 5 or 6 weeks

    Participants are randomized to a 4, 5 or 6 week waiting period/baseline. Repeated measurements (twice a week) are being collected throughout this period.

Interventions

  • BehavioralVulvodynia Intervention: a multimodal treatment for provoked vulvodynia

    The intervention is based around physiological and psychosocial components working with goal-directed behavioral change. Includes both educational and practical elements, examples of these are vulva care, lubrication exercises, pelvic floor relaxation, work with thoughts, feelings, and behaviors related to the pain, as well as thoughts, feelings and behaviors related to sex and desire, and educational and practical elements focusing on open communication and validation. The treatment sessions are approximately 60 minutes each. There is a possibility for the participants to involve partner during two of the treatment sessions.

06

What researchers measure

Primary outcomes

  1. Change in pain during touch and/or insertion of an object

    Provoked pain during sexual and non-sexual activities. Seven activities where pain is rated on a scale from 0 to 10. Higher scoring indicates higher degree of pain. There are also subsequent questions regarding whether they have performed the described activity or not within a specific time frame.

    Time frame: Pre, post treatment (25 weeks after the baseline measurement started) and at 6 month follow-up, during baseline (4, 5 or 6 weeks) and treatment period measured twice a week for 25 weeks.

Secondary outcomes

  1. Change in sexual function

    The Female Sexual Function Index (FSFI) is a self-report measure of female sexual function that assesses six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. It consists of 19 questions, rated on a 5-point scale, with a higher score indicating a better sexual function.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

  2. Change in treatment goal attainment

    Participants chose an individual treatment goal and rate treatment goal attainment, from 0-10, 0= the goal is not at all achieved, 10= the goal is achieved.

    Time frame: Pre, post treatment (25 weeks after the baseline measurement started) and at 6 month follow-up. Repeated measures twice a week during baseline (4, 5 or 6 weeks) and treatment period, for 25 weeks.

  3. Change in pelvic floor tension

    Self-report assessment of pelvic floor tension and pelvic floor relaxation. Two items rated on a 11-point scale, from 0-10, higher scores indicate greater tension and more difficulty relaxing the pelvic floor, and physiotherapeutic examination.

    Time frame: Pre, post treatment (25 weeks after the baseline measurement started) and at a 6 month follow-up. During baseline and treatment period measured twice a week, for 25 weeks.

  4. Change in sexual satisfaction

    Global measure of sexual satisfaction (GMSEX), 5 items rated on a 7-point scale. Higher scores indicate a higher degree of sexual satisfaction.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

  5. Change in interpersonal and self focused sexual goals

    Approach avoidance sexual goals (AASQ), self focused sexual goals and interpersonal sexual goals, 23 items rated on a 7-point scale, participants rates the importance of self focused or interpersonal reasons, influencing why they typically engage in sex. Higher scores indicates greater importance.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started), and at 6 months follow-up

  6. Change in perceived intimacy

    9 items regarding self and partner disclosure, partner responsiveness and closeness, rated on a 7-point scale, with higher scores indicating greater perceived intimacy.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started), and at 6 months follow-up

  7. Change in life interference, sexual function interference and impact on relationship

    Vulvar pain assessment questionnaire (VPAQ) Inventory is a disease-specific set of measurement scales to capture the biopsychosocial nature of vulvodynia. We are using the parts from the questionnaire that evaluates life interference, sexual function interference, impact on relationship and sexual communication. Life interference: 11 items rated on a 6-point scale from 0 (not at all) to 4 (avoid because of pain). Higher scores indicating greater life interference. Sexual function interference: 10 items rated on a 6-point scale from 0 (not at all) to 4 (avoid because of pain) Impact on relationship: 6 items about intimacy and, general and sexual communication rated on a 5-point scale from much worse to much better. Higher scoring indicates that the vulva pain has lower impact on the relationship. 6 items about communication with partner rated on a 5-point scale from 0 (largely uncomfortable) to 4 (largely comfortable). Higher scoring indicates

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

  8. Change in depressive symptoms

    Using the patient health questionnaire (PHQ-9), 9 items are rated on a 4-point scale, from 0 to 3. Higher scores indicating higher degree of depression symtoms.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

  9. Change in anxiety symptoms

    Using the Generalized Anxiety Disorder questionnaire (GAD-7), 7 items rated on a 4-point scale from 0 to 3, higher scoring indicating a higher degree of anxiety symptoms.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

  10. Change in quality of life

    World Health Organization Quality of Life-BREF, 1 item where participants rates their quality of life, on a 5-point scale from 1 to 5, higher scoring indicating greater quality of life.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

Other outcomes

  1. Evaluation of how much time participants spend on the treatment and related exercises

    Time frame: during treatment period

  2. Demographic

    Age, country of birth, educational level, occupation, if they have a partner/-s, how long they have been in that relationship/-s, gender of partner/-s, if they have kids, childbirth during the last year, ongoing pregnancy, menstruation

    Time frame: Pre treatment (25 weeks after the baseline measurement started). Questions about partner/-s are measured pre and post treatment (25 weeks after the baseline measurement started) and at 6 month follow-up.

  3. Change in sexual desire and arousal

    Two items from the female sexual function index, measuring sexual desire and arousal, rated on a 5-point scale. Higher scoring indicate greater sexual desire and arousal.

    Time frame: Repeated measure twice a week during baseline and treatment period, for 25 weeks.

  4. Change in pain catastrophizing

    Pain catastrophizing scale (PCS) evaluates participants negative cognitive and emotional reactions to pain. It assesses the extent of catastrophic thinking due to pain according to three subscales: rumination, magnification and helplessness. 13 items rated on a 5-point scale from 0 (not at all) to 4 (all the time). Higher scores indicating greater levels of pain catastrophizing.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

  5. Change in avoidance and endurance related to sexual activities

    Two items from the CHAMP Sexual Pain Coping Scale (CSPCS), rated on a 7-point scale, with higher scores indicating a higher degree of avoidance and endurance.

    Time frame: Repeated measure twice a week during baseline and treatment period, for 25 weeks

  6. Experiences of sexual and physical abuse

    Using the Sexual and Physical Abuse Questionnaire (SPAQ). 8 questions about experiences of sexual and physical abuse.

    Time frame: Pre treatment

  7. Treatment expectations

    2 items rated on a 11-point scale, from 0 to 10. Higher scoring indicating higher expectations that this treatment will be helpful.

    Time frame: Pre treatment

  8. Negative treatment effects

    1-2 items measuring negative effects of the treatment. One questions that asks if the participant experienced any negative effects of the treatment, with a following question asking the participant to describe more in an open answer.

    Time frame: Post treatment (25 weeks after the baseline measurement started)

  9. Perceived treatment improvement and satisfaction

    4 items rating potential improvement and satisfaction on a 6-point scale (1-6), higher scoring indicating greater improvement and satisfaction.

    Time frame: Post treatment (25 weeks after the baseline measurement started)

  10. Change in sexual pain coping

    Using items from the CHAMP Sexual Pain Coping Scale, 12 items assess coping strategies for sexual pain: avoidance and endurance, rated on a 7 point-scale from 1 to 7, where higher scoring indicating a higher degree of avoidance and/or endurance.

    Time frame: Pre and post treatment (25 weeks after the baseline measurement started) and at 6 months follow-up

  11. Experience of treatment

    Semi structured interviews, individual interviews and focus groups, probing qualitative aspects of the treatment experience, and the experience of implementation of patients, treating practitioners and clinical managers.

    Time frame: Post treatment (25 weeks after the baseline measurement started)

07

Study locations

1 site
  • Karlstad University
    Karlstad, Sweden
08

References and documents

Individual participant data

Plan to share: No — Because of the sensitive nature of the data. Data can be provided by request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 32 non-industry interventional studies with no phase under Vulvodynia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 21 months is below that.

Counting every sponsor, half of 32 studies reached it within 36 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
May 21, 2025
StartActual
Mar 11, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06981611
Lead sponsor
Karlstad University
Collaborators
Region Stockholm, Region Örebro County, Region Jönköping County, Region Värmland
Responsible party
Ida Flink (Professor in psychology, Karlstad University) — Principal investigator
First posted
May 21, 2025
Start date
Mar 11, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion